



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid Drug Utilization Review (DUR) Board

Thursday, May 10, 2018, 2:00pm

DMAS Board Room 13th Floor

Agenda

1. **Call to Order and Introductions** – Bill Rock, PharmD, Chair
2. **Minutes**
 - a. Approval of Minutes from March 22, 2018 meeting
3. **New Drugs**
 - a. Biktarvy® (bictegravir, emtricitabine, and tenofovir alafenamide)
 - b. Erleada™ (apalutamide)
 - c. Symdeko™ (tezacaftor/ivacaftor); (ivacaftor)
 - d. Symfi Lo™ (efavirenz, lamivudine and tenofovir disoproxil fumarate)
 - e. New Drugs: New Generics; New Dosage Form or Strength; PDL-Eligible; Physician-Administered Injectables
4. **RetroDUR Criteria Estimates**
5. **Topics for Discussion**
 - a. Orphan Drugs
 - b. Acute Dosing of Proton Pump Inhibitors
 - c. Gender Edit for Point of Sale System
 - d. Pediatric and Adult Opioid Utilization
 - e. Naloxone Utilization Review
 - f. Analysis of Compounded Medications
 - g. DUR Quarterly Newsletter
6. **Reports**
 - a. ProDUR
 - b. RetroDUR
 - c. Utilization Analysis
 - d. Top Diagnoses by Age
 - e. AAP Report
7. **Adjournment**